Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications
- PMID: 16857573
- DOI: 10.1016/S1474-4422(06)70521-X
Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications
Abstract
Levodopa-induced motor complications are a common source of disability for patients with Parkinson's disease. Evidence suggests that motor complications are associated with non-physiological, pulsatile stimulation of dopamine receptors. In healthy brains, dopamine neurons fire continuously, striatal dopamine concentrations are relatively constant, and there is continuous activation of dopamine receptors. In the dopamine-depleted state, standard levodopa therapy does not normalise the basal ganglia. Rather, levodopa or other short-acting dopaminergic drugs induce molecular changes and altered neuronal firing patterns in basal ganglia neurons leading to motor complications. The concept of continuous dopaminergic stimulation proposes that continuous delivery of a dopaminergic drug will prevent pulsatile stimulation and avoid motor complications. In monkeys treated with MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) and patients with Parkinson's disease, long-acting or continuous infusion of a dopaminergic drug reduces the risk of motor complications. The current challenge is to develop a long-acting oral formulation of levodopa that provides clinical benefits but avoids motor complications.
Similar articles
-
The therapeutic concept of continuous dopaminergic stimulation (CDS) in the treatment of Parkinson's disease.Parkinsonism Relat Disord. 2009 Dec;15 Suppl 3:S68-71. doi: 10.1016/S1353-8020(09)70784-9. Parkinsonism Relat Disord. 2009. PMID: 20083012 Review.
-
Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease.Nat Clin Pract Neurol. 2006 Jul;2(7):382-92. doi: 10.1038/ncpneuro0222. Nat Clin Pract Neurol. 2006. PMID: 16932589 Review.
-
An approach to the continuous dopaminergic stimulation in Parkinson's disease.Isr Med Assoc J. 2012 Mar;14(3):175-9. Isr Med Assoc J. 2012. PMID: 22675859 Review.
-
Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments.Eur Neurol. 2008;60(2):57-66. doi: 10.1159/000131893. Epub 2008 May 15. Eur Neurol. 2008. PMID: 18480609 Review.
-
Levodopa in the treatment of Parkinson's disease: current controversies.Mov Disord. 2004 Sep;19(9):997-1005. doi: 10.1002/mds.20243. Mov Disord. 2004. PMID: 15372588 Review.
Cited by
-
Application of OpenArray Technology to Assess Changes in the Expression of Functionally Significant Genes in the Substantia Nigra of Mice in a Model of Parkinson's Disease.Genes (Basel). 2023 Dec 12;14(12):2202. doi: 10.3390/genes14122202. Genes (Basel). 2023. PMID: 38137024 Free PMC article.
-
Effects and molecular mechanism of chitosan-coated levodopa nanoliposomes on behavior of dyskinesia rats.Biol Res. 2016 Jul 4;49(1):32. doi: 10.1186/s40659-016-0093-4. Biol Res. 2016. PMID: 27378167 Free PMC article.
-
β-arrestin2 alleviates L-dopa-induced dyskinesia via lower D1R activity in Parkinson's rats.Aging (Albany NY). 2019 Dec 18;11(24):12315-12327. doi: 10.18632/aging.102574. Epub 2019 Dec 18. Aging (Albany NY). 2019. PMID: 31891566 Free PMC article.
-
Long-term results of carbidopa/levodopa enteral suspension across the day in advanced Parkinson's disease: Post-hoc analyses from a large 54-week trial.Clin Park Relat Disord. 2022 Dec 20;8:100181. doi: 10.1016/j.prdoa.2022.100181. eCollection 2023. Clin Park Relat Disord. 2022. PMID: 36594071 Free PMC article.
-
Pharmaceutical and pharmacokinetic evaluation of a newly formulated multiparticulate matrix of levodopa and carbidopa.ADMET DMPK. 2022 Oct 15;11(1):97-115. doi: 10.5599/admet.1474. eCollection 2023. ADMET DMPK. 2022. PMID: 36778908 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical